WO2001009116A3 - A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE - Google Patents
A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE Download PDFInfo
- Publication number
- WO2001009116A3 WO2001009116A3 PCT/US2000/016333 US0016333W WO0109116A3 WO 2001009116 A3 WO2001009116 A3 WO 2001009116A3 US 0016333 W US0016333 W US 0016333W WO 0109116 A3 WO0109116 A3 WO 0109116A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperidin
- benzo
- methoxyphenyl
- phenoxy
- ethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63356/00A AU6335600A (en) | 1999-07-29 | 2000-07-17 | A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride |
EP00950223A EP1204656A2 (en) | 1999-07-29 | 2000-07-17 | A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |
US10/031,326 US6653479B1 (en) | 1999-07-29 | 2000-07-17 | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14628699P | 1999-07-29 | 1999-07-29 | |
US60/146,286 | 1999-07-29 | ||
US14757099P | 1999-08-06 | 1999-08-06 | |
US60/147,570 | 1999-08-06 | ||
US14977399P | 1999-08-19 | 1999-08-19 | |
US60/149,773 | 1999-08-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001009116A2 WO2001009116A2 (en) | 2001-02-08 |
WO2001009116A3 true WO2001009116A3 (en) | 2001-05-17 |
Family
ID=27386379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/016333 WO2001009116A2 (en) | 1999-07-29 | 2000-07-17 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
Country Status (45)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001009115A2 (en) * | 1999-07-29 | 2001-02-08 | Eli Lilly And Company | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
EP1757291A3 (en) * | 2000-05-08 | 2009-07-15 | Eli Lilly & Company | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
US7122203B2 (en) | 2000-05-08 | 2006-10-17 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
DZ3376A1 (en) * | 2000-05-08 | 2001-11-15 | Lilly Co Eli | STABILIZED FORMULATIONS OF 6-HYDROXY-3- (4- [2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY) -2- (4-METHOXYPHENYL) BENZO [B] THIOPHENE AND SALTS THEREOF |
EP1157996A1 (en) * | 2000-05-23 | 2001-11-28 | JENAPHARM GmbH | New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on |
UA76124C2 (en) * | 2000-10-20 | 2006-07-17 | Lilly Co Eli | A crystal form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride, pharmaceutical composition and a method for producing |
US6921827B2 (en) | 2000-11-27 | 2005-07-26 | Eli Lilly And Company | Process for preparing 3-aryl-benzo{b} thiophenes |
CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
PT1773811E (en) * | 2004-07-22 | 2010-10-19 | Lilly Co Eli | A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0729956A1 (en) * | 1995-02-28 | 1996-09-04 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
WO1998045287A1 (en) * | 1997-04-09 | 1998-10-15 | Eli Lilly And Company | Treatment of central nervous system disorders with selective estrogen receptor modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
ZA9710262B (en) * | 1996-11-19 | 1999-05-13 | Lilly Co Eli | Process for the synthesis of benzothiophenes |
-
2000
- 2000-07-17 WO PCT/US2000/016333 patent/WO2001009116A2/en not_active Application Discontinuation
- 2000-07-17 EP EP00950223A patent/EP1204656A2/en not_active Ceased
- 2000-07-17 AU AU63356/00A patent/AU6335600A/en not_active Abandoned
- 2000-07-18 LV LVP-00-94A patent/LV12623B/en unknown
- 2000-07-21 RO ROA200000736A patent/RO121851B1/en unknown
- 2000-07-24 CZ CZ20002716A patent/CZ299311B6/en not_active IP Right Cessation
- 2000-07-24 ID IDP20000629D patent/ID27078A/en unknown
- 2000-07-25 HR HR20000503A patent/HRP20000503B1/en not_active IP Right Cessation
- 2000-07-27 NL NL1015821A patent/NL1015821C2/en not_active IP Right Cessation
- 2000-07-27 IL IL13755300A patent/IL137553A/en not_active IP Right Cessation
- 2000-07-27 CO CO00056521A patent/CO5180570A1/en active IP Right Grant
- 2000-07-27 TR TR2000/02206A patent/TR200002206A2/en unknown
- 2000-07-28 DE DE10036854A patent/DE10036854A1/en not_active Withdrawn
- 2000-07-28 LU LU90617A patent/LU90617B1/en active
- 2000-07-28 PL PL00341749A patent/PL341749A1/en not_active Application Discontinuation
- 2000-07-28 MX MXPA00007461A patent/MXPA00007461A/en active IP Right Grant
- 2000-07-28 HU HU0003001A patent/HUP0003001A2/en unknown
- 2000-07-28 IT IT2000MI001759A patent/IT1318660B1/en active
- 2000-07-28 DK DK200001151A patent/DK200001151A/en not_active Application Discontinuation
- 2000-07-28 SE SE0002792A patent/SE0002792L/en unknown
- 2000-07-28 FI FI20001722A patent/FI20001722A/en unknown
- 2000-07-28 JP JP2000228939A patent/JP2001064277A/en active Pending
- 2000-07-28 NO NO20003879A patent/NO20003879L/en not_active Application Discontinuation
- 2000-07-28 BE BE2000/0478A patent/BE1013411A3/en not_active IP Right Cessation
- 2000-07-28 FR FR0009969A patent/FR2796944B1/en not_active Expired - Fee Related
- 2000-07-28 GB GB0018641A patent/GB2352717A/en not_active Withdrawn
- 2000-07-28 MY MYPI20003453A patent/MY128764A/en unknown
- 2000-07-28 SG SG200004288A patent/SG91296A1/en unknown
- 2000-07-28 LT LT2000076A patent/LT4790B/en not_active IP Right Cessation
- 2000-07-28 CN CNB001222376A patent/CN1138770C/en not_active Expired - Fee Related
- 2000-07-28 AT AT0132400A patent/AT502318A1/en not_active Application Discontinuation
- 2000-07-28 SI SI200000172A patent/SI20426A/en not_active IP Right Cessation
- 2000-07-28 KR KR1020000043651A patent/KR100697177B1/en not_active IP Right Cessation
- 2000-07-28 CA CA002314682A patent/CA2314682A1/en not_active Abandoned
- 2000-07-28 SV SV2000000132A patent/SV2002000132A/en unknown
- 2000-07-28 AR ARP000103928A patent/AR031073A1/en unknown
- 2000-07-28 BR BR0003209-3A patent/BR0003209A/en not_active Application Discontinuation
- 2000-07-28 UA UA2000074563A patent/UA72885C2/en unknown
- 2000-07-28 GR GR20000100265A patent/GR1004084B/en unknown
- 2000-07-28 PT PT102502A patent/PT102502A/en not_active IP Right Cessation
- 2000-07-28 MD MDA20000162A patent/MD2336G2/en not_active IP Right Cessation
- 2000-07-28 TW TW089115154A patent/TWI276437B/en not_active IP Right Cessation
- 2000-07-29 DZ DZ000126A patent/DZ3060A1/en active
- 2000-07-31 PE PE2000000757A patent/PE20010385A1/en not_active Application Discontinuation
-
2001
- 2001-09-03 HK HK01106204A patent/HK1035370A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0729956A1 (en) * | 1995-02-28 | 1996-09-04 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
WO1998045287A1 (en) * | 1997-04-09 | 1998-10-15 | Eli Lilly And Company | Treatment of central nervous system disorders with selective estrogen receptor modulators |
Non-Patent Citations (1)
Title |
---|
RABASSEDA, X. ET AL: "Arzoxifene hydrochloride", DRUGS FUTURE (1999), 24(6), 599-604, XP002159973 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001009115A3 (en) | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE | |
WO2001009116A3 (en) | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | |
JO2239B1 (en) | Process for the preparation of benzothiophene derivatives | |
WO2003051860A3 (en) | Substituted 2-phenyl benzofurans as estrogenic agents | |
WO2002034741A3 (en) | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | |
TH55348B (en) | New crystal form of 6-hydroxy-3- (4- [2-piperidin-1-il) ethoxi] phenoxy) -2- (4-methylphenyl) benzo [3] Thiophene Hydrochloride | |
AU5531001A (en) | Stabilized formulations of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl) benzo(B)thiophene and salts thereof | |
RU2000120575A (en) | NEW CRYSTALLINE FORM of 6-HYDROXY-3- (4- [2- (PIPERIDIN-1-IL) ETOXY] PHENOXY) -2- (4-METHOXYPHENYL) BENZE [b] THIOPHENE HYDROCHLORIDE | |
CY2344B1 (en) | A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride. | |
TJ20000620A (en) | A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxy Ü phenoxy) - 2 - (4-methanoxyphenyl) benzo ÄbÜ thiophene hidrochloride | |
TJ398B (en) | A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10031326 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000950223 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000950223 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWR | Wipo information: refused in national office |
Ref document number: 2000950223 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000950223 Country of ref document: EP |